Neurologic Clinics 2005: Vol 23 Index

2005·5 MB·English

NEUROLOGIC
ELSEVIER CLINICS
SAUNDERS
Neurol Clin 23 (2005) 1225-1253
Cumulative Index 2005
Vote: Page numbers of article titles are in boldface type.
A A ging
ABC. See Activities-Specific Balance change-in-supp ctions due to,
Confidence (ABC). 759-762
mechanis . 163-764
Absence epilepsy, during sleep, 1134 CNS effects o
Abuse effects on vest
alcohol Agrypnia excitata,
neuropathy due to, 377-379
parkinsonism due to, 438 Alcohol abuse
drug, neuropathy due to, 377-379 neuropathy due t
parkinsonism du
Acceleration, in aviation environment,
543-544 Alcoholic myopathy
Acetylcholine, effects on sleep, 972-975 ALL. See Acute leukemia
{LL).
Acid secretion, during sleep, 1012-1013
ALS. See Amyotre SCl|e rOan SIS
Acoustic neuroma, surgical treatment of, ALS).
887-889
Alternative agents nia, 1159
Acrylamide, neuropathy due to, 384
Aluminum
Activities-Specific Balance Confidence ALS due to, 465
(ABC), 793-794 Alzheimer’s diss
Acute disseminated encephalomyelitis, 490-492
92-93 myoclonus due
MS and, 93-96 Parkinson’s dise
toxicity of, 359
Acute hemorrhagic leukoencephalitis,
93 Alzheimer’s disease
aluminum and
Acute lymphoblastic leukemia (ALL), copper and, 492
therapeutic irradiation for, impact of, environmenta effects on,
581-582 488-497
Acute nonrecurring spontaneous vertigo. heavy metals at
in children, 810 iron and, 492-4
magnetic fields
Acute quadriplegic myopathy, 414-416 manganese and
pesticides and, 4
Acute radiation syndrome, 573
smoking and, 49
Addict(s), frozen, 345-348 solvents and, 488
zine and, 492-4
Adhesion molecules
in circulation, OSA and, 1067-1068 Amiodarone, amp! ig myopathy
in MS, selective expression of, 158 due to, 405-406
Agent Orange, neuropathy due to, Amphetamine(s), ne
385-386 379-380
0733-8619/05/$ - see front matter © 2005 Elsevier Inc. All rights reserved
doi: 10.1016/S0733-8619(05)00074-5 neurologic.theclinics.com
1226 CUMULATIVE INDEX
Amphibia, envenomations and poisonings Anthrax, as neurobiological weapon,
due to, 554-555 608-609
Amphiphilic drug myopathy, 404-406 Antiadhesion molecule therapy, for MS,
amiodarone in, 405-406 overview of, 236-238
chloroquine in, 404-405
Antibody(ies)
hydroxychloroquine in, 405
monoclonal. See Monoclonal
Amyotrophic lateral sclerosis (ALS) antibodies.
case-control studies of, 463-464 neutralizing, with interferons, in MS,
cigarette smoking and, 468-469 207-209
diet and, 473-474
Antibody responses, in MS, selective
environmental influences on, 461-484
expression of, 160-161
aluminum, 465
chemicals, 466-470 Anticholinergic(s)
cigarette smoking, 468-469 effects on sleep, 1191
diet, 473-474 for vestibular function suppression,
electrical shock, 471-472 833-835
electromagnetic fields, 471-472
farming, 467-468 Anticonvulsant(s), for nerve agent—related
Gulf War service, 469-470 injuries, 635-636
heavy metals, 464-466 Antidepressant(s)
infections, 470-471 for EDS, 1036-1037
lead, 464 for insomnia, 1159-1160
manganese, 466
mercury, 464-465 Antiemetic(s), in emesis suppression,
physical factors, 472-473 836-838
selenium, 465-466
Antihistamine(s), for vestibular function
solvents, 468 suppression, 835
toxins, 466-470
trace elements, 464-466 Antimicrotubular myopathies, 406-407
tumors, 471 colchicine in, 406
environmental toxins in, 506-512 vincristine in, 406-407
farming and, 467-468
Anxiety disorders, somatoform dizziness as
in Gulf War veterans, 469-470
expression of, 738-739
infections and, 470-471
magnetic fields and, 506-507 Anxiety-related dizziness, case study of,
metals and, 506 929-93]
overview of, 461-463
Apnea, during sleep, scoring of, 997-998
Persian Gulf War and, 507-508
physical factors and, 472-473 Arousal(s)
sleep and, 1212-1213 CNS. See Central nervous system
Western Pacific, 474-476 CNS) arousals
Amyotrophic lateral sclerosis disorders of, in NREM sleep,
1080-1083
parkinsonism-dementia complex
(ALS/PDC) of Guam, 436, 508-509 Arrhythmia(s), cardiac, in NREM sleep,
cyad and, 510-512 1089
metals and, 510
neuropathology of, 509-510 Arsenic
neuropathy due to, 380
Anatoxin-a, as neurobiological weapon, toxicity of, 357-358
611-612
Arthropod(s), envenomations and
Anemia, schistosomiasis and, 563 poisonings due to, 557-558
Angina pectoris, nocturnal, in NREM sleep, Ascending reticular system, 947-948
1089 effects on sleep, 972-979
Animal(s), toxicity of, 371-372 Asthma, nocturnal, in NREM sleep, 1089
Ankylosing spondylitis, radiation exposure Ataxia, multiple sclerosis and,
in, wn5 75 181-182
CUMULATIVE INDEX 1227
Atherogenesis hearing loss and, 819
sleep apnea and, 1068-1069 labyrinthitis and, 813
sleep-disordered breathing and, Meniere’s disease and, 813-814
cerebrovascular disease due to, migraine and, 814-815
1061-1062 motion sickness and, 817
: non-neurotologic disorders and,
Atherosclerosis, 1061 818-819
Atomic bomb survivors, radiation exposure nonvertiginous dysequilibrium
in, ‘ 578 and, 816-819
otitis media and, 816-817
Atropine, for nerve agent-—related injuries, perilymphatic fistula and,
633-634 "812-813
Audiologic examination, in evaluation of recurrent vertige and, 813-815
balance disorders in children, 822-823 seizure disorders a 815
vestibular evalt 1 of,
Autism, neurodevelopmental toxicology 819-827
‘a nd, 333-33 a; udioliong ic exameirneaettsi on in,
822-823
Autoimmune disease
described, 150-151 dynamic platform
MS as, 151-152 posturography in,
, : QI5_RIG
Autoimmunity, described, 150-151 electronystagmography in,
— : 893-895
Autonomic disorders, in Parkinson’s = ee 997
. imaging in, 826-82
disease, effects on sleep, 1200 sli
laboratory evaluation in,
Aviation environment 823-826
neurology of, 541-547 motor functioning tests in,
acceleration in, 543-544 821-822
hypoxia, 542-543 patient h
water environment and, shared 8] 2
stressors in, 544-547. See also physical ex
Water environment, aviation 820
environment and, shared : vestibular neur
stressors in. in older persons, 7
Axon(s), chronically demyelinated, in MS, Cone — myers BE
aa ten 116 : significance of, 85 86
management of, 793-794
Axonal loss vestibular disorders and,
immune-mediated, in MS, 112-114 786-787
in MS. 110-112 physical therapy for, 855-874
inflammatory demyelination and, contraindications to, 857-858
relationship between, 98-99 efficacy of, 86¢
ae Se evaluation of, 858-861
Azathioprine, for MS, 263 factors affecting. 863-865
indications for, 857
physiologic basis of
B specialists in, locatins
Balance, physiologic basis of, 808-810 treatment of, 861-863
Balance disorders Balance systems, in older persons, failure of,
: ee Be ER oie
exercise for, 855—856 87-793
in children, 807-829 Ballismus, toxin-induced, 440-44]
acute nonrecurring spontaneous
vertigo, 810 Balo’s concentric sclerosis, 90-92
er vestibulas B-cell responses, in MS, selective expression ’
CNS disorders and, 817-818 oS, 1O-10)
drug-induced dizziness and, 818 Benign epilepsy of childhood, with
familial periodic ataxia and, 815 centrotemporal spikes, during sleep,
head trauma and, 810-812 1133
1228 CUMULATIVE INDEX
Benign paroxysmal positional vertigo Bruininks-Oseretsky Test of Motor
(BPPV) Proficiency (BOTMP), in evaluation of
case study of, 921-923 balance disorders in children, 821-822
migraine and, 724-725
Bruxism, in NREM sleep, 1085-1086
surgical treatment of, 880-881
treatment of, drugs in, 842-843 Buckthorn neuropathy, 391
Benign recurrent vertigo of childhood, case
study of, 931-932
Benzodiazepine(s) ‘ancer, ALS due to, 471
for vestibular function suppression,
835-836 N‘Rar bamate(s)
hypnotic efficacy studies of, 955 toxicity of, 368-369
toxicology of, neurodevelopmental.,
Bilateral peripheral vestibular loss, balance 323211-232342
disorders in children due to, 816
Cf arbon disulfide
Bilateral vestibular paresis, treatment of, neuropathy due to, 385
drugs in, 846
parkinsonism due to, 434
Biologic agents, for HSCT, 287 toxicity of, 363-364
Biomarker(s), of inflammation, in MS, a arbon monoxide
135-138 parkinsonism due to, 435-436
Parkinson’s disease due to, 503
Bioscavenger(s), for nerve agent-related toxicity of, 367
injuries, 638-639
aC ‘ardiac arrhythmias, in NREM sleep, 1089
Biphenyl(s), polychlorinated.
neurodevelopmental toxicology of, ‘ase studies, 919-933
329-33 anxiety-related dizziness, 929-931
benign recurrent vertigo of childhood,
Bismuth, myoclonus due to, 442 931-932
Bladder, MS effects on, management of, BPPV, 921-923
182 Meniere’s disease, 923-925
migraine-related dizziness, 925-929
Blood—brain barrier, immune cells and, vestibular neuritis, 919-921
interaction of, in MS, 158-166
~ ‘ataplexy, 1028
BOTMP. See Bruininks-Oseretsky Test of sleep-onset, 954
Motor Proficiency (BOTMP).
atathrenia, in NREM sleep, 1085
Botulinum toxin
as neurobiological weapon, 601-606 NKnn ‘atechol-O-methyltransferase inhibitors,
characteristics of, 601-603 effects on sleep, 1191
clinical aspects of, 604-606 rs CHS. See Congenital central
deployment methods, 603-604 hypoventilation syndrome (CCHS
Bowel, MS effects on, management of, C ell(s), endothelial, in circulation, OSA
182-183 and, 1067-1068
BPPV. See Benign paroxysmal positional oC ellular neurotoxicology, overview of,
vertigo (BPP\ 311-314
Brain, electrical activity of, 946-947 ~ ‘entral nervous system (CNS)
Brain tumors, therapeutic irradiation for, aging effects on, 791-792
impact of, 582-583 immune reactivation and effector
mechanisms within, in MS,
Brainstem disorders, abnormal eye 161-162
movements in, 692 parasomnias of, 1088
Breastfeeding. MS and, 49 schistosomiasis effects on, 563-565
toxins of, radiation, 571-597. See
Breathing disorders, during sleep, 994 also Radiation, nervous system
scoring of, 997-999 injuries due to.
CUMULATIVE INDEX 1229
Central nervous system (CNS) arousals, Chemokine receptors MS. selective
during sleep, 994 expression of, 158-15
scoring of, 996
Chemotherapy, for schistosomiasis, 567
Central nervous system (CNS) disorders,
Children
balance disorders in children due to,
817-818 balance disorders in, 807-829.
See also Ba wders
Central nervous system (CNS) ontogeny, in children
3275-377 migrainous vertig 18-719
restless legs syndrome in, 1166-1167
Central sleep apnea, 1051-1052
Chloroquine, amphip] nyopathy
Central vertigo, treatment of, drugs in,
due to, 404—405
846-848
Cholesteatoma, surgic ent of,
Central vestibular disorders
884-885
abnormal eye movements in,
692-699 Cholesterol-lowering dt necrotizing
physical examination of, 663 myopathies due to, 398-402
Cerebellar disorders, abnormal eye Chorea, toxin-induced, 440-44
movements in, 698-699
Choreoathetosis, toxin-it ced, 440-441
Cerebellar dysfunction, migraine and,
Chromosome 6p21.3, in MS, 64-68
725-726
Chromosome 17q21-23 MS, 69-70
Cerebral schistosomiasis, 565-567
Cerebrovascular disease, sleep-disordered Chromosome 19q13, in MS, 69
breathing and, 1059-1075. See also Chronic obstructive pu ry disease
Sleep-disordered breathing, (COPD), sleep-relats 052-1053
cerebrovascular disease and.
Chronobiology, 949
Cerebrovascular events, schistosomiasis
and, 565 Cigarette smoking, ALS due to, 468-469
Change-in-support balance reactions, in Ciguatera neuropathy
older persons, 751-783 Circadian rhythm, 98\
biomechanics of, 754-759
clinical assessment of, 769-772 Circadian rhythm dis p effects on,
compensatory vs. volitional limb 1198
movement in, 755 Circadian rhythm sleep disorders, 1190
control mechanisms in, 755-75
control of, interventions in, 773-776 Clock genes, 98]
described, 751—754, 759-764
Cnidaria, envenomati poisonings
environment constraints effects on,
due to, 556
757-759
mechanisms of, 763—764 CNS. See Central nei m (CNS
medical conditions and, 764-769
Cochicine, antimicrotub ypathies
neural control in, 754-759
due to, 406
ongoing activity related to, 757-759
Parkinson’s disease and, 764-769 Cognition, MS effects igement of,
strategies for, 754—755 184
stroke-related hemiparesis and,
764-766 Cognitive impairment, in Parkinson's
disease, effects on s 199-1200
Chemical(s)
ALS due to, 466-470 Cognitive-behavioral the ’r insomnia,
organic, neuropathy due to, 1158-1159
380-387 Colonic motility, during
Chemical Weapons Convention, 625 1019-1020
Chemokine(s), in MS, selective expression Compensation, agents aff
of, 158-159 838-840
1230 CUMULATIVE INDEX
. -¢ s .
Compensatory limb movement, volitional with Lewy bodies, Parkinson’s disease
limb movement vs., in change-in- vs., 498-499
support balance reactions in older
Dental procedures, radiation exposure in,
persons, 755
S75
Congenital central hypoventilation
Depersonalization syndrome, dizziness as
syndrome (CCHS), 1053
expression of, 742
Congenital myopathy, sleep and, 1216-1217
Depression, 1190-1191
Conjugate gaze, mechanism of, 682-683 in Parkinson’s disease, effects on
sleep, 1198-1199
Continuous oscillopsia, 711
MS and, management of, 183-184
Contraceptive(s), in MS patients, 50
Depressive disorders, somatoform dizziness
COPD. See Chronic obstructive pulmonary as expression of, 740-741
disease (COPD
Derealization syndrome, dizziness as
Copper, Alzheimer’s disease and, 492-494 expression of, 742
Copper sulfate, Parkinson’s disease and, Desynchrony, forced, during sleep, 983-984
502
Devic’s disease, 94-96
Cortical disorders, abnormal eye natural history of, 20-21
movements in, 698
DHI. See Dizziness Handicap Inventory
Cramp(s), muscle, nocturnal, in NREM DH1).
sleep, 1091-1092
Diet, ALS due to, 473-474
C-reactive protein, in OSA, 1068
Diffuse esophageal spasm, in NREM
Critical illness myopathy, 414-416 sleep, 1090
Cyad, ALS/PDC of Guam due to, Dioxin, neuropathy due to, 385-386
510-512
Diphenylether(s), polybrominated,
Cyad seed, parkinsonism due to, 436-438 neurodevelopmental toxicology of,
329-33
Cyanide, parkinsonism due to, 435
Disability(ies), neurologic, in MS, 108-110
Cyclophosphamide, for MS, 248-256
cortical lesions and, 121
clinical studies of
initial, 249 Disabling positional vertigo, surgical
‘randomized, 249-252 treatment of, 886-887
recent, 252-253
Disjunctive movements, 678
current clinical use, 256
described, 248-249 Dissociative disorders, somatoform
immunologic effects, 253-254 dizziness as expression of, 741
safety of, 254-256
Diving, scuba, environmental issues in,
Cyclosporine, necrotizing myopathies due 548-549
to, 403
Dizziness
Cytokine(s), sleep apnea and, 1068-1069 abnormal eye movements with,
675-703
D in peripheral vestibular disorders,
690-692
Decompression sickness, in aviation and
anxiety-related, case study of, 929-931
water environments, 546-547
as expression of depersonalization or
Dementia derealization syndrome, 742
demographics of, 486-487 balance disorders in older persons and,
diagnosis of, 487-488 functional significance of,
frontotemporal, environmental toxins 785-786
in, 505 bedside assessment of
Parkinson’s disease, 498 circumstance in, 659-660
screening for, 487-488 dysequilibrium in, 657
CUMULATIVE INDEX 1231
effect on patient's life, 660 for central vertigo, 846-848
floating, swimming, and spinning for dizziness, 831-853. See also
inside of head in, 659 Dizziness f
lightheadedness in, 657 for Meniere’s disease, 843-844
medications taken in, 660 for psychogenic vertigo, 848
motion sickness in, 658 for vertigo of undetermined or ill-
nausea and vomiting in, 658 defined causes, 84!
oscillopsia in, 658-659 for vestibular { on suppression,
patient history in, 655-673 833-836
patient’s thoughts on, 660 for vestibular ne 844-846
rocking or swaying in, 657-658 hypokalemic myop lue to. 417
symptoms in, 657 illicit, myopathies due 420-421
tempo in, 655 in emesis suppress 836-838
vertical diplopia in, 659 inflammatory n hy due to,
vertigo in, 659 410-412. See specific drug,
drug-induced, balance disorders in e.g., Phen
children due to, 818 injectable, MS effe 85-186
migraine-related, case study of. mitochondrial s due to,
925-929 407-410. See specific drug,
neurophysiology of, 831-832 e.g., Zido
nonvestibular, migraine and, 726-727 myopathies due 4 $2]
physical examination of, 660-672 pated
"central vestibular disorders, 663 Drug abuse, neuropat : shi
gait, 671-672 Duction, defined, 677
maneuver-induced vertigo and :
eye movements, 668-669 Dynamic platform pos aphy, in
peripheral vestibular disorder, evaluation of ba sorders in
661-663 children, 825-826
skew deviation, 663-664 Dysequilibrium, non is, balance
spontaneous nystagmus, 661-663 disorders in childret e to, 816-819
stance, 671-672
visual tracking in, 669-671 Dyskinesia(s), respirat NREM sleep,
VOR abnormalities, 664-667 "1089
somatoform. See Somatoform Byuctoniatc)
dizziness. . nocturnal paroxys 135
treatment of, drugs in, 831-853 parkinsonism duc 138 440
agents of uncertain efficacy o1
mechanism, 840-842
anticholinergics, 833-835 y
antihistamines, 835 iienetnemerinsiielieat eet
benzodiazepines, 835-836 Eating disorders, sleep n NREM
compensatory agents, 838-840 sleep, 1083-1085
Dizziness Handicap Inventory (DHI), 793 EDS. See Excessive ess
EDS
Dizziness History Form, 797-799
Elderly. See also Ok
Dopamine, effects on sleep, 976
balance disorders 1 785-805. See also
: j es
Dopaminergic agonists, effects on sleep, Balance d ut
119] persons
sleep in, 1188~1
Downbeat nystagmus, abnormal eye
movements in, 695 Electrical shock, ALS 171-472
on 1 tic feld< AIS on AT 79
Dream(s), interpretation of, Sigmund Freud Electromagnetic field I 0, 471-472
948-949 , .
and, 948-94 Electronystagmograph iation of F
Drug(s) balance disorders dren, 823-825
dizziness due to, balance disorders in Emesis, suppression of, dru 836838
children due to, 818
for BPPV, 842-843 Emetrine, myopathy due to, 414
CUMULATIVE INDEX
Encephalitis/encephalomyelitis, lizard, 554
schistosomiasis and, 565 marine animal, 555-55
mollusca, 556
Encephalomyelitis
newt, 555
acute disseminated, 92-93
porifera, 556
MS and, 93-96
protista, 555-556
perivenous, 92
reptile, 553-554
Encephalopathy(ies), toxic, 353-376 scorpion, 558
aluminum and, 359 snake, 554
animals and, 371-372 ney 557-558
arsenic and, 357-358 tick, 558
carbamates and, 368-369 toz d, 554
carbon disulfide and, 363-364
Environment(s)
carbon monoxide and, 367
as factor in ALS, 461-484
ethanol and, 365-366
as factor in change-in-support balance
heavy metals, 354—-360
reactions in older persons,
hexacarbon solvents and, 364-365
757-759
insects and, 371-372
aviation, neurology of, 541-547.
lead and, 354-356
See also Aviation environment,
manganese nr 3 58-359
neurology of.
Marchiafava-Bignami disease, 366
marine toxins and, 370 37] Environmental issues, in scuba diving,
mercury and, 356 35 548-549
mushrooms and, 370
Environmental toxins, neurodegenerative
natural neurotoxins and, 369-372
memory disorders due to, 485-521.
organophosphates and, 368
See also Memory disorders,
perchlorethylene and, 362-363
neurodegenerative, environmental
pesticides and, 368-369
toxins in.
plants and, 369-370
scorpions and, 372 Epilepsy
snake venoms and, 371 absence, during sleep, 1134
solvents and, 361 Pe frontal lobe, during sleep, 1130-1132
spider venoms and, 37 ~ i) mechanisms of, 1127-1128
styrene and, 364-365 schistosomiasis and, 565
thallium and, 360 sleep and, 1127-1147. See also Sleep,
tin and, 360 epilepsy and.
toluene and, 361 sleep disorders and, 1143-1144
trichlorethylene and, 362 temporal lobe, during sleep, 1129-1130
vapors and, 361-367 with generalized tonic-clonic seizures
Wernicke-K orsakoff syndrome, 366 on awakening, 1134
xylene and, 364-365
Epileptic disorders, probable, 1135-1138
mere surgical treatment
of, 875-87 Epileptic syndromes, sleep-related,
1128-1138
Endothelial cells, in circulation, OSA and,
1067-1068 Erection(s)
painful, in REM sleep, 1121
Endothelial dysfunction, in sleep helene 1, penile, in REM sleep, 1121
1069-1070
Ergotism, 348-350, 392
Enuresis, in NREM sleep, 1086
Ethanol, toxicity of, 365-366
Envenomation(s)
amphibia, 554 Ethylene oxide, neuropathy due to, 386
arthropod, § Excessive daytime sleepiness (EDS)
cnidaria, 556 clinical significance of, 959-960
fauna-related, 553-558 in Parkinson’s disease, 1191-1193
fish, 556-557 nervous system disorders and,
frog, 554-555 1033-1034
hymenoptera, 558 primary
CUMULATIVE INDEX ia
conditions of, 1025-1044 Familial periodic ataxia, balance disorders
management of, 1034-1037 in children due to, 815
Exercise Farming
for balance disorders, 855-856 effects on ALS, 467-468
for vestibular dysfunction, 855-856 Parkinson’s disease and, 501
MS and, management of, 184
Fatigue
Exploding head syndrome, 1088 MS and, 177-178
sleepiness and, in Parkinson’s disease,
Extraocular muscles
1191
actions of, in eye movement, 678-679
innervation of, in eye movement, Fauna
675-676 envenomations due to, 553-558
poisonings due to, 553-558
Eye movements
abnormal Fibric acid derivatives, necrotizing
in brainstem disorders, 692 myopathies due to, 398
in central vestibular disorders,
692-699 Fibrosis(es), hepatic, schistosomiasis and,
cerebellar disorders, 698-699 562
cortical disorders, 698 Fish, envenomations and poisonings due to,
dizzy patients, 675-703 556-557
downbeat nystagmus, 695
SSBBB hBoriEzo ntal nystagmus, Fistula(s), perilymphatic
692-693 balance disorders in children due to,
lateropulsion of saccades, 693 812-813
palatal tremor, 693-694 surgical treatment of, 885-886
Sss pser iodic alternating Freud, Sigmund, in interpretation of
nystagmus, 693 dreams, 948-949
pitch plane disorders, 693
roll plane disorders, 695-696 Frog(s), envenomations 1d poisonings due
thalamic disorders, 696-698 to, 554-555
1 torsional nystagmus, 696
Frontal lobe epilepsy, during sleep
in upbeat nystagmus, 694-695 1130-1132
ocular tilt reaction, 696
skew deviation and, 696 Frontotemporal dementia, environmental
basics of, 675-690 toxins in, 505
conjugate gaze in, mechanism
Frozen addicts, 345-348
682-683
extraocular muscles in Functional disorders, in NREM sleep, 1091
actions of, 678-679
Fungicide(s), Parkinson’s disease and, 500
innervation of, 675-676
gaze holding in, 681—682
maneuver-induced, physical
examination of, 668-669 G
neural integrator in, 681-682
Gait, physical examination of, 671-672
optokinetic reflex, 689-690
pulleys in, 679-680 Gastric functioning, durin 2 sieep,
saccades, 684—687 1012-1015
smooth pursuit, 687-689
Gastroesophageal reflux (GER)
subdivision of, 683-690
during sleep, 1007-1012
terminology related to, 676-678
in NREM sleep, 1090
torsional, 676
VOR in, 680 Gastrointestinal tract
NREM parasomnias effects on, 1090
sleep and, 1007-1024. See also Sleep,
gastrointestinal tract and.
Fall(s), among older persons, 785 upper, functioning during sleep,
vestibular disorders and, 786-787 1007-1012
Fall-related injuries, in older persons, 785 Gaze, conjugate, mechanism of, 682-683
1234 CUMULATIVE INDEX
Gaze holding, in eye movement, 681-682 Hallucination(s)
hypnagogic, 1028-1029
Geader, in MS, 39-60. See also Multiple
hypnopompic, 1028-1029
sclerosis (MS), gender issues in.
in Parkinson’s disease, effects on sleep,
Gene(s), clock, 981 1201
Genetic(s) Haplotype(s), HLA, REM sleep behavior
of MS, 61-75. See also Multiple disorder and, 1117
sclerosis (MS), genetics of.
Head thrust test, in VOR examination, 665
of restless legs syndrome, 1169-1170
Head trauma, balance disorders in children
Genetic neurotoxicology, overview of,
due to, 810-812
314-316
Headache(s)
GER. See Gastroesophageal reflux (GER).
hypnic, in NREM sleep, 1088
Ginger jake paralysis, 338-341 in NREM sleep, 1088
nonvascular, in NREM sleep, 1088
Glatiramer acetate vascular, in NREM sleep, 1088
for MS, 215-231
chronic progressive, clinical trials Head-shaking nystagmus test, in VOR
of, 223-224 examination, 665-666
clinical trials of, 218-228
Hearing aids
MRI studies, 224-226
fitting protocols for, 904
phase III trial extension,
orientation to, 913
221-223
preselection of, 906-911
pilot trial, 218-219
presetting of, 911-913
pivotal trial of relapsing-
validation of, 914-915
remitting MS, 219-221
verification of, 911-913
preliminary studies, 218
historical background of, Hearing disorders, psychogenic, neuro-
215-216 otologic disorders and, 745-746
in combination therapy, 227-228
Hearing loss, 901-918
in neuroprotection, 228
balance disorders in children due to,
mechanism of action of, 216-217
819
primary progressive disease,
described, 901—903
clinical trial of, 226
evaluation of, 904-906
with interferon, 227
hearing aids for, fitting protocols for,
with natalizumab, 227-228
904
oral, for MS, 226-227
population with, 904
with interferon, for MS, 227
prevalence of, 904
with natalizumab, for MS, 227-228
sensorineural, sudden, neuro-otologic
Glomerulonephritis, schistosomiasis and, disorders and, 744-745
562-563
Heart failure, sleep-related, 1052
Groaning, nocturnal, in NREM sleep, 1085
Heat-related illnesses, 558-559
Gulf War syndrome, 523-540
Heavy metals
defined, 524-525
ALS due to, 464-466
studies addressing, 528-535
Alzheimer’s disease and, 490
toxic exposures and, 525-526
neuropathy due to, 380-387
associations between, 527-535
toxicity of, 354-360
process of, 527
measurement of, 525-526 ematopoietic stem cell transplantation
Gulf War veterans (GWV), 523 (HSCT)
ALS in, 469-470 for aggressive MS, 273-300
animal studies of, 277-279
biologic agents in, 287
ex vivo manipulation of stem cell
H graft in, 286-287
Hallpike-Dix test, in maneuver-induced future considerations in, 292-294
vertigo and eye movements, 668 graft source in, 285-286